Leerink analyst Paul Matteis notes that while Phase 3 data from GW Pharmaceuticals' Epidiolex study in Dravet Syndrome presented at the American Epilepsy Society were "slightly less robust" than that generated in Lennox Gastaut Syndrome, he remains confident that the trial is very likely to be supportive of approval in the U.S. and Europe. The analyst continues to recommend the stock given his expectation of approval, a fast launch, and a robust commercial opportunity in an area of very high unmet medical need. Matteis reiterates an Outperform rating on the shares.